Abaloparatide
FDA APPROVED
Extensively Studied
Healing
Abaloparatide
34
Amino acids
Molecular weight
Peptide
Type
Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.
Top researched benefits
Overview of Abaloparatide
Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.
Osteoporosis Fdaapproved
- FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.
- FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.
Bone Health Research
- Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.
- ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.
Storage
Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Frequency
Once daily
Typical Dose
80 mcg
Cycle Duration
Up to 2 years (lifetime maximum)
Chemical Makeup
Key benefits
FDA-approved for osteoporosis treatment
Actively builds new bone (anabolic mechanism)
Superior hip BMD gains vs teriparatide in trials
Reduces vertebral fracture risk significantly
Reduces nonvertebral fracture risk
Lower hypercalcemia risk than teriparatide
Works through selective PTH1R activation
Benefits seen within 6 months
Community interest
This peptide is still gaining traction in the community.
PTHrP Analog | Anabolic Bone-Building Agent
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesAbaloparatide Molecular Information
View the scientifc details of Abaloparatide.
34
Amino Acids
Abaloparatide
Ala
Ala
Position 1
Val
Val
Position 2
Ser
Ser
Position 3
Glu
Glu
Position 4
His
His
Position 5
Gln
Gln
Position 6
Leu
Leu
Position 7
Leu
Leu
Position 8
His
His
Position 9
Asp
Asp
Position 10
Lys
Lys
Position 11
Gly
Gly
Position 12
Lys
Lys
Position 13
Ser
Ser
Position 14
Ile
Ile
Position 15
Gln
Gln
Position 16
Asp
Asp
Position 17
Leu
Leu
Position 18
Arg
Arg
Position 19
Arg
Arg
Position 20
Arg
Arg
Position 21
Glu
Glu
Position 22
Leu
Leu
Position 23
Leu
Leu
Position 24
Glu
Glu
Position 25
Lys
Lys
Position 26
Leu
Leu
Position 27
Leu
Leu
Position 28
?
?
Position 29
Lys
Lys
Position 30
Leu
Leu
Position 31
His
His
Position 32
Thr
Thr
Position 33
Ala
Ala
Position 34
Molecular Weight
3961DaChain Length
34Amino AcidsType
PeptideAbaloparatide Protocols
Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 80 | 1 week range | SubQ (periumbilical abdomen) |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Store pen refrigerated at 2-8°C (do not freeze)
- Allow to reach room temperature before injection
- Attach new needle for each injection
- Inject subcutaneously in periumbilical region
- Rotate injection sites
- Discard pen after 30 days even if medication remains
Abaloparatide Cycle
The Abaloparatide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Month 1-3
- Bone formation markers increase; initial BMD changes begin
- Month 3-6
- Significant BMD increases at spine, hip, and femur
- Month 6-12
- Continued bone density improvements; fracture risk reduction
- Month 12-18
- Maximum benefits in ACTIVE trial; substantial fracture reduction
- Month 18-24
- Transition to maintenance therapy (e.g., bisphosphonates) recommended
Dosing tools
Abaloparatide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
Abaloparatide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Abaloparatide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- Abaloparatide
- Dosing
- 80 mcg
- Dosing Frequency
- Once daily
- Cycle Duration
- Up to 2 years (lifetime maximum)
- Storage
- Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Abaloparatide interactions with other common peptides and substances.
Healing
ter
Teriparatide
AVOID
Do not use concurrently; both are PTH receptor agonists. Choose one or use sequentially.
Side effects
Avoid: Do not take Abaloparatide with Teriparatide.
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Stop signs
Signs of hypercalcemia (confusion, fatigue, excessive thirst)
Persistent bone pain
Severe dizziness or fainting
Allergic reactions
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
AbaloparatideResearch References
Abaloparatide is an extensively studied compound
Abaloparatide
Abaloparatide is an extensively studied compound
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial)
Abaloparatide showed substantial reduction in vertebral fractures and greater BMD increases at spine, hip, and femur compared to placebo and teriparatide.
n.d.
ACTIVExtend Trial: Abaloparatide Followed by Alendronate
18 months abaloparatide followed by alendronate significantly reduced vertebral and nonvertebral fractures.
n.d.
Phase 2 Dose-finding Study of BA058 in Postmenopausal Women
Significant BMD increases at 40 and 80 mcg doses; abaloparatide showed superior anabolic effects on hips vs teriparatide.
n.d.
Profile of Abaloparatide and Its Potential in Postmenopausal Osteoporosis
Abaloparatide preferentially binds RG conformational state of PTH1R, producing more anabolic bone effects.
n.d.